Endocrine Effects of the Tyrosine Kinase Inhibitor Vandetanib in Patients Treated for Thyroid Cancer
Authors:
- Maryse BrassardMBMaryse Brassard
- Barbara NeraudBNBarbara Neraud
- Séverine TrabadoSTSéverine Trabado
- Sylvie SalenaveSSSylvie Salenave
- Sylvie Brailly-TabardSBSylvie Brailly-Tabard
- Isabelle BorgetIBIsabelle Borget
- Eric BaudinEBEric Baudin
- Sophie LeboulleuxSLSophie Leboulleux
- Philippe ChansonPCPhilippe Chanson
- Martin SchlumbergerMSMartin Schlumberger
- Jacques YoungJYJacques Young
- 1 September 2011
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 96 (9) , 2741-2749